Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAdagene Inc

Adagene Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.12 USD 0.00(0%)
Last update at 2026-11-09T21:00:00Z
VOLUME
158551
Market Cap
251.08M

Momentum Score

…

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.08
Low
2.27
High
52 Week Price Range
1.30
Low
4.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Adagene Inc is a NASDAQ‑listed biopharmaceutical company that works on antibody therapeutics and immuno‑oncology; publicly available detail on its programs and platform is limited. Its long‑term growth may be driven by clinical progress of pipeline candidates, validation of its discovery platform, and business development or licensing that extend resources and market reach. Investors may find the company attractive for potential milestone‑driven upside if clinical programs advance and partners are secured.

Key risks include high clinical and regulatory uncertainty, significant cash‑burn and financing needs, intense competition in the antibody/oncology field, and dependence on successful trial outcomes and deal execution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.12
Dividend Yield
-
Revenue TTM
7.67M
Revenue Per Share
0.16
Gross Profit TTM
7.67M
Debt / Equity
0.18
ROE
-34.39%
Net Debt
-68.26M
ROCE
-40.49%
Diluted EPS TTM
-0.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -17.91M -33.44M -17.25M -79.51M -71.48M
Net income -17.61M -33.42M -18.95M -79.97M -73.18M
Selling general administrative 7.08M 7.27M 8.67M 11.87M 14.44M
Selling and marketing expenses - - 0.01M - -
Gross profit 7.67M -0.82M 18.11M 9.29M 10.18M
Reconciled depreciation 0.59M 0.94M 1.21M 1.45M 1.13M
Ebit -21.49M -32.59M -16.16M -83.92M -72.36M
Ebitda -20.91M -31.66M -14.95M -81.37M -70.51M
Depreciation and amortization 0.58M 0.93M 1.21M 2.55M 1.85M
Operating income -21.44M -35.95M -23.72M -83.92M -72.36M
Other operating expenses 29.11M 36.05M 41.83M 93.21M 82.54M
Interest expense 0.46M 0.85M 1.11M 0.69M 0.36M
Tax provision -0.30M -0.02M 1.69M 0.46M 1.70M
Interest income 2.30M 3.80M 4.28M 0.38M 0.08M
Net interest income 1.84M 2.95M 3.18M -0.32M -0.29M
Income tax expense -0.30M -0.02M 1.69M 0.46M 1.70M
Total revenue 7.67M 0.10M 18.11M 9.29M 10.18M
Total operating expenses 29.11M 36.05M 41.83M 93.21M 82.54M
Cost of revenue - 0.93M - - -
Total other income expense net 3.53M 2.51M 6.46M 4.41M 0.89M
Net income from continuing ops -17.61M -33.42M -18.95M -79.97M -73.18M
Net income applicable to common shares - - - - -73.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 78.26M 89.27M 115.73M 152.40M 189.51M
Other current assets 2.83M 2.58M 3.29M 4.94M 4.06M
Total liab 42.91M 38.74M 45.17M 69.31M 32.95M
Total stockholder equity 35.35M 50.52M 70.56M 83.09M 156.56M
Other current liab 12.75M 15.52M 19.72M 22.54M 16.50M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -328.79M -311.18M -277.75M -258.81M -178.83M
Other liab - - - 0.03M 0.14M
Other assets - -0.02M 0.00M 0.11M 0.07M
Cash 74.52M 85.19M 109.93M 143.76M 174.39M
Total current liabilities 25.17M 38.18M 31.46M 55.08M 29.82M
Current deferred revenue 3.46M - 0.05M 15.11M 5.50M
Net debt -68.26M -66.70M -87.63M -115.79M -166.90M
Short term debt 5.07M 17.93M 8.59M 13.77M 4.50M
Short long term debt 4.98M 17.79M 8.40M 13.62M 4.50M
Short long term debt total 6.26M 18.49M 22.31M 27.97M 7.49M
Other stockholder equity 366.04M 362.22M 350.11M 342.74M 335.48M
Property plant equipment - - - 2.97M 3.49M
Total current assets 77.38M 87.78M 113.44M 149.32M 185.95M
Net tangible assets - - - 83.09M 156.56M
Net receivables 0.02M 0.01M 0.22M 0.62M 7.51M
Long term debt 1.14M 0.42M 13.54M 14.15M 2.99M
Accounts payable 2.88M 4.24M 3.09M 3.67M 3.32M
Accumulated other comprehensive income -1.91M -0.53M -1.80M -0.85M -0.09M
Non currrent assets other 0.03M 0.10M 0.08M 0.11M 0.07M
Non current assets total 0.89M 1.51M 2.29M 3.08M 3.56M
Capital lease obligations 0.15M 0.28M 0.37M 0.21M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.49M 1.11M -0.08M -0.69M -2.51M
Change to liabilities - - - 0.00M 6.33M
Total cashflows from investing activities 0.48M 1.11M -0.08M - -2.51M
Net borrowings -12.24M -3.42M -5.37M - -0.70M
Total cash from financing activities 4.45M 3.77M -5.37M 17.82M 145.36M
Change to operating activities - - - - 4.36M
Net income -17.61M -33.42M -18.95M -79.97M -73.18M
Change in cash -10.67M -24.74M -33.82M -30.63M 99.24M
Begin period cash flow 85.19M 109.93M 143.76M 174.39M 75.15M
End period cash flow 74.52M 85.19M 109.93M 143.76M 174.39M
Total cash from operating activities -15.66M -29.70M -28.45M -48.61M -43.41M
Issuance of capital stock 16.55M 7.33M 0.00M 0.00M 149.79M
Depreciation 0.59M 0.93M 1.21M 1.45M 1.13M
Other cashflows from investing activities 0.00M 0.00M 0.01M - -
Dividends paid - - - - 4.61M
Change to inventory - - - - 6.02M
Change to account receivables -0.01M 0.21M 0.40M 3.00M -3.00M
Sale purchase of stock - 0.00M 0.00M -3.98M -2.36M
Other cashflows from financing activities 16.55M -0.14M 0.01M 26.15M 7.63M
Change to netincome - - - - 19.29M
Capital expenditures 0.02M 0.03M 0.09M 0.69M 2.51M
Change in working capital -0.78M -1.89M -16.55M 21.94M 9.35M
Stock based compensation 3.74M 4.91M 7.27M 10.52M 18.68M
Other non cash items -1.60M -0.22M -1.44M -2.55M -0.01M
Free cash flow -15.67M -29.73M -28.54M -49.30M -45.92M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ADAG
Adagene Inc		 -
-%		 2.12 - - 32.73 7.27 24.61 1.12
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Adagene Inc

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Building C14, Suzhou, China, 215123

86 512 8777 3632

https://www.adagene.com

128

Name Title Year Born
Dr. Peter P. Luo Ph.D. Co-Founder, CEO & Chairman 1966
Mr. Man Kin Tam M.B.A. CFO & Director 1977
Dr. Fangyong Du Ph.D. Chief Technology Officer 1970
Dr. Jc Xu M.D., Ph.D. Chief Scientific Officer 1965
Ms. Ami Celeste Knoefler VP of Investor Relations & Corp. Communications NA
Ms. Ling Zhou Head of HR NA
Dr. Qinghai Zhao Chief Manufacturing Officer 1961
Ms. Yan Li M.B.A. Sr. VP of Bioinformatics & Information Technology 1975
Ms. Xiaohong She Sr. VP & Head of Clinical Operations 1967
Dr. Guizhong Liu Ph.D. Head of Biology & Pharmacology 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…